Latest News

Price of alirocumab would have to be cut to be cost-effective

(HealthDay)—For patients with a recent acute coronary syndrome receiving a statin, the price of alirocumab would have to be reduced to be cost-effective, according to a study published online Jan. 1 in the Annals of Internal Medicine.

Source link

Related posts

Medical News Today: Through my eyes: Cannabinoid hyperemesis syndrome (CHS)


Medical News Today: What causes a loss of appetite?


Medical News Today: Regular sleep schedule likely benefits metabolic health


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy